Triple

T20301452
Position Surface form Disambiguated ID Type / Status
Subject Alexion Pharmaceuticals E505487 entity
Predicate developsTreatmentFor P69333 FINISHED
Object neuromyelitis optica spectrum disorder
Neuromyelitis optica spectrum disorder is a rare autoimmune disease in which the immune system attacks the optic nerves and spinal cord, leading to episodes of vision loss and paralysis.
E1423953 NE FINISHED

How this triple was built (4 steps)

Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.

NER Named-entity recognition gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: neuromyelitis optica spectrum disorder | Statement: [Alexion Pharmaceuticals, developsTreatmentFor, neuromyelitis optica spectrum disorder]
NED1 Entity disambiguation (via context triple) gpt-5-mini-2025-08-07
Target entity: neuromyelitis optica spectrum disorder
Context triple: [Alexion Pharmaceuticals, developsTreatmentFor, neuromyelitis optica spectrum disorder]
  • A. ADEM
    ADEM is the state agency responsible for administering and enforcing environmental laws and regulations in Alabama.
  • B. relapsing-remitting multiple sclerosis
    Relapsing-remitting multiple sclerosis is the most common form of multiple sclerosis, characterized by clearly defined attacks of neurological symptoms followed by periods of partial or complete recovery.
  • C. Guillain–Barré syndrome
    Guillain–Barré syndrome is an acute autoimmune disorder in which the immune system attacks peripheral nerves, leading to rapidly progressive muscle weakness and potential paralysis, often triggered by infections such as Campylobacter.
  • D. Neurology: Neuroimmunology & Neuroinflammation
    Neurology: Neuroimmunology & Neuroinflammation is a peer-reviewed medical journal focusing on research at the intersection of the nervous and immune systems, including mechanisms and treatment of neuroinflammatory and neuroimmunologic diseases.
  • E. progressive multifocal leukoencephalopathy
    Progressive multifocal leukoencephalopathy is a rare, often fatal demyelinating brain disease caused by reactivation of the JC virus in immunocompromised individuals, leading to rapidly progressive neurological decline.
  • F. None of above. chosen
  • G. Unsure - the case is ambiguous/there is not enough information to decide.
NEDg Description generation gpt-5.1
Instruction
Generate a one-sentence description of the target entity. 
You are given a context triple in the form (subject, predicate, object), where the object is the target entity. 
# Instructions
Use the triple to infer relevant information about the entity. Describe the entity based on what is most defining, well-known. 
Avoid repeating the information from the triple, unless really essential.
# Response Format
Return only the sentence: "Description: [one-sentence description of the target entity]"
Input
Entity: neuromyelitis optica spectrum disorder
Triple: [Alexion Pharmaceuticals, developsTreatmentFor, neuromyelitis optica spectrum disorder]
Generated description
Neuromyelitis optica spectrum disorder is a rare autoimmune disease in which the immune system attacks the optic nerves and spinal cord, leading to episodes of vision loss and paralysis.
NED2 Entity disambiguation (via description) gpt-5-mini-2025-08-07
Target entity: neuromyelitis optica spectrum disorder
Target entity description: Neuromyelitis optica spectrum disorder is a rare autoimmune disease in which the immune system attacks the optic nerves and spinal cord, leading to episodes of vision loss and paralysis.
  • A. ADEM
    ADEM is the state agency responsible for administering and enforcing environmental laws and regulations in Alabama.
  • B. relapsing-remitting multiple sclerosis
    Relapsing-remitting multiple sclerosis is the most common form of multiple sclerosis, characterized by clearly defined attacks of neurological symptoms followed by periods of partial or complete recovery.
  • C. Guillain–Barré syndrome
    Guillain–Barré syndrome is an acute autoimmune disorder in which the immune system attacks peripheral nerves, leading to rapidly progressive muscle weakness and potential paralysis, often triggered by infections such as Campylobacter.
  • D. Neurology: Neuroimmunology & Neuroinflammation
    Neurology: Neuroimmunology & Neuroinflammation is a peer-reviewed medical journal focusing on research at the intersection of the nervous and immune systems, including mechanisms and treatment of neuroinflammatory and neuroimmunologic diseases.
  • E. progressive multifocal leukoencephalopathy
    Progressive multifocal leukoencephalopathy is a rare, often fatal demyelinating brain disease caused by reactivation of the JC virus in immunocompromised individuals, leading to rapidly progressive neurological decline.
  • F. None of above. chosen

Provenance (5 batches)

The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.

Step Stage Batch ID Status When
creating Elicitation batch_69e0b4b8ab648190906e18538c250148 completed April 16, 2026, 10:06 a.m.
NER Named-entity recognition batch_69e6770c700c81909da247cef0d0f1eb completed April 20, 2026, 6:57 p.m.
NED1 Entity disambiguation (via context triple) batch_6a08611762e481909ee2f41434c86aa5 completed May 16, 2026, 12:20 p.m.
NEDg Description generation batch_6a0863506f4481909c106c49f6b71191 completed May 16, 2026, 12:30 p.m.
NED2 Entity disambiguation (via description) batch_6a0863f4bb788190b6ef1fe57279badb completed May 16, 2026, 12:32 p.m.
Created at: April 16, 2026, 11:17 a.m.